TACSTD2 and breast carcinoma: The most significant and clinically important observation in the current study is the upregulation of Trop-2 by tamoxifen because it provides a method to improve the efficacy of sacituzumab govitecan treatment, not only for TNBC but also for luminal breast cancer.